AU2014247979B2 - Inhibitors of metastasis - Google Patents

Inhibitors of metastasis Download PDF

Info

Publication number
AU2014247979B2
AU2014247979B2 AU2014247979A AU2014247979A AU2014247979B2 AU 2014247979 B2 AU2014247979 B2 AU 2014247979B2 AU 2014247979 A AU2014247979 A AU 2014247979A AU 2014247979 A AU2014247979 A AU 2014247979A AU 2014247979 B2 AU2014247979 B2 AU 2014247979B2
Authority
AU
Australia
Prior art keywords
ala
glu
prt
lys
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014247979A
Other languages
English (en)
Other versions
AU2014247979A1 (en
Inventor
Kenneth B. Adler
Indu Parikh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Carolina State University
Biomarck Pharmaceuticals Ltd
Original Assignee
North Carolina State University
Biomarck Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina State University, Biomarck Pharmaceuticals Ltd filed Critical North Carolina State University
Publication of AU2014247979A1 publication Critical patent/AU2014247979A1/en
Application granted granted Critical
Publication of AU2014247979B2 publication Critical patent/AU2014247979B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Virology (AREA)
AU2014247979A 2013-04-05 2014-04-07 Inhibitors of metastasis Ceased AU2014247979B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361808966P 2013-04-05 2013-04-05
US61/808,966 2013-04-05
PCT/US2014/033206 WO2014165853A1 (en) 2013-04-05 2014-04-07 Inhibitors of metastasis

Publications (2)

Publication Number Publication Date
AU2014247979A1 AU2014247979A1 (en) 2015-10-29
AU2014247979B2 true AU2014247979B2 (en) 2018-06-28

Family

ID=51654619

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014247979A Ceased AU2014247979B2 (en) 2013-04-05 2014-04-07 Inhibitors of metastasis

Country Status (19)

Country Link
US (4) US9408886B2 (cg-RX-API-DMAC7.html)
EP (1) EP2981279B1 (cg-RX-API-DMAC7.html)
JP (1) JP6449849B2 (cg-RX-API-DMAC7.html)
KR (1) KR102191695B1 (cg-RX-API-DMAC7.html)
CN (1) CN105517562B (cg-RX-API-DMAC7.html)
AU (1) AU2014247979B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015025398A2 (cg-RX-API-DMAC7.html)
CA (1) CA2908832C (cg-RX-API-DMAC7.html)
DK (1) DK2981279T3 (cg-RX-API-DMAC7.html)
ES (1) ES2714863T3 (cg-RX-API-DMAC7.html)
HU (1) HUE043971T2 (cg-RX-API-DMAC7.html)
IL (1) IL241937B (cg-RX-API-DMAC7.html)
MX (1) MX363077B (cg-RX-API-DMAC7.html)
PL (1) PL2981279T3 (cg-RX-API-DMAC7.html)
PT (1) PT2981279T (cg-RX-API-DMAC7.html)
RU (1) RU2681213C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201708125PA (cg-RX-API-DMAC7.html)
WO (1) WO2014165853A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201508010B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2681213C2 (ru) 2013-04-05 2019-03-05 Байомарк Фармасьютикалз, Лтд. Ингибиторы метастазирования
CN108686220A (zh) * 2018-07-13 2018-10-23 刘慧荣 一种针对甲状腺癌的抗肿瘤剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057305A2 (en) * 2006-10-27 2008-05-15 George Mason Intellectual Properties, Inc. Assay for metastatic colorectal cancer
US20090203620A1 (en) * 2006-07-26 2009-08-13 Indu Parikh Methods for attenuating release of inflammatory mediators and peptides useful therein

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
AU2002322475B2 (en) 2001-06-26 2008-02-21 North Carolina State University Blocking peptide for inflammatory cell secretion
AU2002362753B9 (en) * 2001-10-05 2008-05-15 The Trustees Of The University Of Pennsylvania Compositions for and methods of treating and preventing sirs/sepsis
DE60308251T2 (de) 2002-04-17 2007-08-30 Canon K.K. Vorrichtung zur Bereitstellung von öffentlichen Schlüsselzertifikaten
US7524926B2 (en) 2005-01-20 2009-04-28 Biomarck Pharmaceuticals, Ltd. Mucin hypersecretion inhibitors and methods of use
WO2006086681A2 (en) * 2005-02-09 2006-08-17 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting smooth muscle cell migration and proliferation
EP2069477A4 (en) 2006-10-06 2010-12-08 Celtaxsys Inc CHEMICAL REPULSION OF CELLS
WO2009062128A2 (en) * 2007-11-08 2009-05-14 Indiana University Research And Technology Corporation Combination drug therapy for the treatment of cancer
EP2105511A1 (en) * 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
US9073974B2 (en) * 2009-12-21 2015-07-07 The Regents Of The University Of California RGD-containing cyclic peptides
JP6225104B2 (ja) * 2011-04-08 2017-11-01 タフツ メディカル センター インコーポレイテッドＴｕｆｔｓ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ，Ｉｎｃ． ペプデューシンの設計および使用
RU2681213C2 (ru) 2013-04-05 2019-03-05 Байомарк Фармасьютикалз, Лтд. Ингибиторы метастазирования

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090203620A1 (en) * 2006-07-26 2009-08-13 Indu Parikh Methods for attenuating release of inflammatory mediators and peptides useful therein
WO2008057305A2 (en) * 2006-10-27 2008-05-15 George Mason Intellectual Properties, Inc. Assay for metastatic colorectal cancer

Also Published As

Publication number Publication date
RU2015146997A (ru) 2017-05-15
CA2908832A1 (en) 2014-10-09
AU2014247979A1 (en) 2015-10-29
EP2981279A4 (en) 2016-11-09
ES2714863T3 (es) 2019-05-30
MX363077B (es) 2019-03-07
KR20150140736A (ko) 2015-12-16
US9408886B2 (en) 2016-08-09
JP6449849B2 (ja) 2019-01-09
SG10201708125PA (en) 2017-11-29
CN105517562B (zh) 2018-12-28
ZA201508010B (en) 2017-01-25
RU2015146997A3 (cg-RX-API-DMAC7.html) 2018-03-13
US20210130403A1 (en) 2021-05-06
WO2014165853A1 (en) 2014-10-09
US11466054B2 (en) 2022-10-11
US20140302057A1 (en) 2014-10-09
NZ712955A (en) 2021-03-26
US20190119320A1 (en) 2019-04-25
PL2981279T3 (pl) 2019-09-30
HUE043971T2 (hu) 2019-09-30
EP2981279A1 (en) 2016-02-10
JP2016516756A (ja) 2016-06-09
KR102191695B1 (ko) 2020-12-16
CN105517562A (zh) 2016-04-20
EP2981279B1 (en) 2018-12-19
US10683328B2 (en) 2020-06-16
MX2015014036A (es) 2016-02-25
IL241937B (en) 2019-03-31
BR112015025398A2 (pt) 2017-10-10
HK1221159A1 (en) 2017-05-26
DK2981279T3 (en) 2019-03-25
PT2981279T (pt) 2019-03-14
US10011636B2 (en) 2018-07-03
US20170121369A1 (en) 2017-05-04
RU2681213C2 (ru) 2019-03-05
SG11201508249WA (en) 2015-11-27
CA2908832C (en) 2023-01-24

Similar Documents

Publication Publication Date Title
US20230145356A1 (en) Use of fak inhibitor in preparation of drug for treating tumors having nras mutation
JP5451378B2 (ja) 内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用
CN101171010B (zh) 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
WO2009026328A2 (en) Methods of delivery of agents to leukocytes and endothelial cells
US20210145825A1 (en) Use of opioid antagonists
KR20130135820A (ko) 중독，정신 장애 및 신경퇴행성 질환 치료용 조성물 및 방법
US20210283068A1 (en) Tumor suppression by modulation of non-canonical autophagy (lap) in myeloid cells
US11466054B2 (en) Inhibitors of metastasis
KR102558988B1 (ko) 항암제 내성을 완화하고 항암제의 민감성을 강화하기 위한 약학적 조성물 및 그 용도
US20150231203A1 (en) Treatment of pain by inhibition of usp5 de-ubiquitinase
US20240075093A1 (en) Compositions and methods of treating a pi3k mediated disease
HK1221159B (en) Mareks inhibitor peptides for inhibiting metastasis
US20220249545A1 (en) Platinum-Based Chemotherapy, Mast Binding Agents, Glucocorticoid Receptor (GR) Binding Agents, and/or HSP90 Binding Agents for Uses in Treating Cancer
WO2025250689A1 (en) Combination therapy with angiogenesis protein and immune checkpoint inhibitor with/without chemotherapeutics
TW201840332A (zh) 用於對抗具抗藥性癌症之組合物及方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired